In a cohort study of 401 patients in Taiwan with EGFR-mutant NSCLC treated with EGFR TKIs, those receiving osimertinib experienced significantly more CTRCEs compared with other EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.